• +357 22 373089
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

GLADIATOR: A paradigm shift in Oncology Research via externally controllable molecular communications for "bio-nano-machine diagnostics"


Next-generation Theranostics of Brain Pathologies with Autonomous Externally Controllable Nanonetworks: a Trans-disciplinary Approach with Bio-nanodevice Interfaces (Grant Agreement number: 828837 — GLADIATOR — H2020-FETOPEN-2018-2020/H2020-FETOPEN-2018-2019-2020-01)

“The only way to predict the future is to invent it…”

 The GLADIATOR FETOpen: Bridging Electrical and Biomedical Engineering, Synthetic Biology and Nano-biotechnology, Cellular Biosciences, Molecular Oncology and Information Technologies, GLADIATOR promises a vanguard and comprehensive theranostic (therapeutic+diagnostic) solution for the management of brain pathologies. Through multi-faceted and targeted breakthroughs, GLADIATOR is going to provide, for the first time, a working prototype of a complete, autonomous and clinically applicable, nanonetwork-based, Molecular Communications platform. This multipotent platform will autonomously monitor the spatiotemporal disease evolution and recurrence and generate an appropriate reprogramming intervention (genetic modification halting the disease) leading to effective therapy and, thus, addressing a high impact societal challenge. The platform will integrate novel, revolutionary, hybrid (electronic + biological) nanosensors, multifunctional autologous organoids and enabling brain molecule-machine interfaces, transforming currently emerging technologies based on the conceptual framework of Externally Controllable Molecular Communications (ECMC). This comprehensive approach, integrating several Key Enabling Technologies, is necessary to address the high complexity of brain pathologies, epitomised by Glioblastoma Multiforme (GBM), the most malignant primary brain tumour. GBM has been selected to provide a proof-of-concept for the applicability of this platform. Despite recent advancements, GBM prognosis is still grim, with a median survival of 14 months1, thus justifying the proposed drastically new approach to attack these highly malignant tumours and, potentially, other brain pathologies. This substantial advancement of concepts and technologies will be breaking the grounds beyond recent “FET portfolio” projects, epitomized by gladiatorimgComputing”, “Complexity”, “Bio&Neuro ICT” and “Quantum & Photonics”. ►Relation to the work programme: The Gatekeepers of FET, Radical Vision, Breakthrough Technological Target and Ambitious Interdisciplinary Research, are addressed explicitly via the following challenges: FET-Open Challenge 1: “Turn Europe’s excellent science base into a competitive advantage by uncovering radically new technological possibilities.” New roadmaps in the management of brain tumours and complex pathologies will be facilitated, establishing the supra-discipline of “bio-nanomachine diagnostics” and renewing ideas towards “nanonetwork therapeutics” with major impact on the pharmaceutical, biotechnology, electrical engineering and IT industry. FET-Open Challenge 2: “Supporting a large set of early-stage, high-risk visionary science and technology collaborative research projects.” GLADIATOR involves farsighted research under a highly interdisciplinary collaboration. The project aspires to attract a gender-balanced group of synthetic biologists, molecular oncologists, engineers, computer scientists and entrepreneurs, cross-fertilizing and channelling fresh ideas between the highly varied backgrounds and expertise of the partner

Dissemination links:

Presentations at National Media:

Within the first 6 months of the project the following presentations/publications have taken place:

  1. Press release in Greek, published in Cypriot education platforms and newspapers:
  2. Article in the leading Cyprus newspaper “Phileleftheros” devoted to GLADIATOR
  3. TV interview of Dr. Andreani Odysseos (EPOS) at the Cyprus “Omega TV”


3 Saint Theophanous Street,
Suite 101,
Nicosia 2055, Cyprus

Telephone: +357 22 373089

Email: inf[at]epos-iasis.com


© 2024 EPOS-Iasis Research and Development, Ltd. All Rights Reserved.